The Industrial Development Corporation (IDC) and China’s Jijia International Medical Technology Company have broken ground on the ZAMVAX vaccine manufacturing plant, Africa’s first cholera vaccine manufacturing facility.
ZAMVAX is a joint venture in which IDC holds 60% and Jijia 40%. The first phase requires an estimated US$24.1 million and is designed to produce up to 20 million oral cholera vaccine doses a year. It follows a memorandum of understanding the partners signed in October 2024.
Health Minister Professor Roma Chilengi, MP, who officiated at the event, credited President Hakainde Hichilema’s advocacy for cholera control and for commercially viable vaccine manufacturing in Africa.
“When we began this journey a few years back, many laughed at the effort. Many thought it was not possible to manufacture vaccines in our setting,” he said. “Today is an important day, because we defy that logic.”
Prof. Chilengi said Zambia depends on a global cholera vaccine stockpile that is always in short supply. The plant will start with OraVacs, the oral cholera vaccine China donated to Zambia, which helped contain an outbreak in Lusaka last year.
“A dependable supply of oral cholera vaccine can strengthen our response alongside safe water, sanitation, surveillance and timely care,” the Minister said.
IDC Chief Executive Officer Cornwell Muleya said the ceremony turned the partnership into a commitment to build lasting productive capacity, built on technology transfer and local participation.
“A groundbreaking is a promise. Its fulfilment will be measured in the vaccines produced, the Zambians equipped with new skills, and the communities that benefit from more reliable access to protection,” Mr Muleya said.
ZAMVAX will begin with solid oral fill-and-finish operations, processing, packaging and quality-testing imported bulk vaccine in Zambia. The next phase adds liquid fill-and-finish for injectable vaccines, working towards end-to-end manufacturing for selected vaccines. Future products may include HPV, malaria and animal vaccines.
Jijia Health Deputy General Manager Xu Yonglin said the company’s role is to build the capacity of Zambian teams to run the facility.
“Technology transfer is successful when the receiving team can carry out its work and take responsibility for product quality,” Mr Xu said.
Speaking on behalf of Chinese Ambassador Han Xing, Embassy Counsellor Mr Wang Shen said the plant “could not come at a better time.”
“As Africa’s first cholera vaccine production project, ZAMVAX not only serves Zambia’s own health security but also undertakes the vital mission of boosting regional public health capacity across Africa,” he said.
He added that the project would help Zambia “evolve from a vaccine importer into a key regional supplier of public health products” and support Africa’s goal of eliminating cholera by 2030.